Pembrolizumab-Olaparib Boosts PFS in Non-BRCA Ovarian Cancer

(MedPage Today) — A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations, a randomized trial showed.
In…

Source link : https://www.medpagetoday.com/meetingcoverage/sgo/114711

Author :

Publish date : 2025-03-18 16:19:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Pembrolizumab-Olaparib Boosts PFS in Non-BRCA Ovarian Cancer

Psychology is revealing how to have a better relationship with money

Ultra-fast chargers can refill electric car batteries in minutes

Related Posts

Better Response, Survival in Head and Neck Cancer With Dual Pre-Op Immunotherapy

Young Patient Dies After Receiving New Gene Therapy for Duchenne Muscular Dystrophy

Texas Midwife Accused by State’s Attorney General of Providing Illegal Abortions

Transplant Doc’s Future in U.S. Uncertain Following Her Deportation to Lebanon

This Vaccine Researcher Was Caught in the NIH Funding Cut Crossfire

Snubbed Vaccine Committee Members Lament FDA’s Flu Shot Actions

Better Response, Survival in Head and Neck Cancer With Dual Pre-Op Immunotherapy

Young Patient Dies After Receiving New Gene Therapy for Duchenne Muscular Dystrophy

Texas Midwife Accused by State’s Attorney General of Providing Illegal Abortions

Transplant Doc’s Future in U.S. Uncertain Following Her Deportation to Lebanon

This Vaccine Researcher Was Caught in the NIH Funding Cut Crossfire

Snubbed Vaccine Committee Members Lament FDA’s Flu Shot Actions

Investigational ADC Shows Promise in Advanced Endometrial Cancer

Experts Sound the Alarm on Pricey Skin Substitutes in Wound Care Industry

Categories

Archives